Detection of fusion gene transcripts in the blood samples of prostate cancer patients

Abstract Prostate cancer remains one of the most lethal cancers for men in the United States. The study aims to detect fusion transcripts in the blood samples of prostate cancer patients. We analyzed nine fusion transcripts including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, CCNH-C5orf30, mTOR-TP53BP...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yan-Ping Yu, Silvia Liu, Joel Nelson, Jian-Hua Luo
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c4edd5c747814d3bad684fb9ac27e34b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c4edd5c747814d3bad684fb9ac27e34b
record_format dspace
spelling oai:doaj.org-article:c4edd5c747814d3bad684fb9ac27e34b2021-12-02T16:46:34ZDetection of fusion gene transcripts in the blood samples of prostate cancer patients10.1038/s41598-021-96528-92045-2322https://doaj.org/article/c4edd5c747814d3bad684fb9ac27e34b2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96528-9https://doaj.org/toc/2045-2322Abstract Prostate cancer remains one of the most lethal cancers for men in the United States. The study aims to detect fusion transcripts in the blood samples of prostate cancer patients. We analyzed nine fusion transcripts including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, CCNH-C5orf30, mTOR-TP53BP1, KDM4-AC011523.2, TMEM135-CCDC67, LRRC59-FLJ60017 and Pten-NOLC1147 in the blood samples from 147 prostate cancer patients and 14 healthy individuals, using Taqman RT-PCR and Sanger’s sequencing. Similar analyses were also performed on 25 matched prostate cancer samples for matched-sample evaluation. Eighty-two percent blood samples from the prostate cancer patients were positive for MAN2A1-FER transcript, while 41.5% and 38.8% blood samples from the prostate cancer patients were positive for SLC45A2-AMACR and Pten-NOLC1, respectively. CCNH-c5orf30 and mTOR-TP53BP1 had low detection rates, positive in only 5.4% and 4% of the blood samples from the prostate cancer patients. Only 2 blood samples were positive for KDM4B-AC011523.2 transcript. Overall, 89.8% patients were positive for at least one fusion transcript in their blood samples. The statistical analysis showed varied sensitivity of fusion transcript detection in the blood based on the types of fusions. In contrast, the blood samples from all healthy individuals were negative for the fusion transcripts. Detection of fusion transcripts in the blood samples of the prostate cancer patients may be a fast and cost-effective way to detect prostate cancer.Yan-Ping YuSilvia LiuJoel NelsonJian-Hua LuoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Yan-Ping Yu
Silvia Liu
Joel Nelson
Jian-Hua Luo
Detection of fusion gene transcripts in the blood samples of prostate cancer patients
description Abstract Prostate cancer remains one of the most lethal cancers for men in the United States. The study aims to detect fusion transcripts in the blood samples of prostate cancer patients. We analyzed nine fusion transcripts including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, CCNH-C5orf30, mTOR-TP53BP1, KDM4-AC011523.2, TMEM135-CCDC67, LRRC59-FLJ60017 and Pten-NOLC1147 in the blood samples from 147 prostate cancer patients and 14 healthy individuals, using Taqman RT-PCR and Sanger’s sequencing. Similar analyses were also performed on 25 matched prostate cancer samples for matched-sample evaluation. Eighty-two percent blood samples from the prostate cancer patients were positive for MAN2A1-FER transcript, while 41.5% and 38.8% blood samples from the prostate cancer patients were positive for SLC45A2-AMACR and Pten-NOLC1, respectively. CCNH-c5orf30 and mTOR-TP53BP1 had low detection rates, positive in only 5.4% and 4% of the blood samples from the prostate cancer patients. Only 2 blood samples were positive for KDM4B-AC011523.2 transcript. Overall, 89.8% patients were positive for at least one fusion transcript in their blood samples. The statistical analysis showed varied sensitivity of fusion transcript detection in the blood based on the types of fusions. In contrast, the blood samples from all healthy individuals were negative for the fusion transcripts. Detection of fusion transcripts in the blood samples of the prostate cancer patients may be a fast and cost-effective way to detect prostate cancer.
format article
author Yan-Ping Yu
Silvia Liu
Joel Nelson
Jian-Hua Luo
author_facet Yan-Ping Yu
Silvia Liu
Joel Nelson
Jian-Hua Luo
author_sort Yan-Ping Yu
title Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_short Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_full Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_fullStr Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_full_unstemmed Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_sort detection of fusion gene transcripts in the blood samples of prostate cancer patients
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/c4edd5c747814d3bad684fb9ac27e34b
work_keys_str_mv AT yanpingyu detectionoffusiongenetranscriptsinthebloodsamplesofprostatecancerpatients
AT silvialiu detectionoffusiongenetranscriptsinthebloodsamplesofprostatecancerpatients
AT joelnelson detectionoffusiongenetranscriptsinthebloodsamplesofprostatecancerpatients
AT jianhualuo detectionoffusiongenetranscriptsinthebloodsamplesofprostatecancerpatients
_version_ 1718383420056272896